Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New obesity drug aims to help keep weight off after switching from popular injections

NCT ID NCT07575399

Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 5 times

Summary

This phase 3 trial tests whether switching from common GLP-1 weight-loss drugs to a new medication called maridebart cafraglutide can help adults with obesity or overweight maintain their weight loss. About 300 participants who have already lost at least 10% of their body weight on a GLP-1 drug will receive injections of the new drug. The main goal is to see how body weight changes over 68 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
maridebart cafraglutide (AMG 133)
What this could lead to
If successful, this could offer a new option for people with obesity to maintain weight loss after switching from common GLP-1 medications.
What could go wrong
This is an early-phase 3 trial with only 300 participants, so results may not apply to everyone. Side effects or lack of weight maintenance are possible risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Body Mass Index (BMI) ≥ 25 at screening. * Weight loss of ≥ 10% on weekly GLP-1 RA. * Stable body weight. * Stable dose of GLP-1RA. * Stable gastrointestinal (GI) tolerability. * Contraception for females. * Willingness to follow trial procedures for the duration of the trial. Exclusion Criteria: * Obesity induced by other endocrine disorders (ex: Cushing's syndrome). * Previous or planned surgical, endoscopic or device-based treatment for obesity. * History of malignancy. * Type 1/Type 2 diabetes mellitus (DM). * Family or personal history of medullary thyroid cancer. * Previous participation in a Maridebart Cafraglutide trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity or overweight

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    45 sites in 2 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Accellacare Research of Wilmington

    RECRUITING

    Wilmington, North Carolina, 28401, United States

  • Accellacare of Raleigh

    RECRUITING

    Raleigh, North Carolina, 27609, United States

  • Aga Clinical Trials

    RECRUITING

    Hialeah, Florida, 33012, United States

  • Altoona Center for Clinical Research

    RECRUITING

    Duncansville, Pennsylvania, 16635, United States

  • Apex Clinical Research

    RECRUITING

    San Diego, California, 92120, United States

  • Arcturus Healthcare, Public Limited Company, Troy Internal Medicine Research Division

    RECRUITING

    Troy, Michigan, 48098, United States

  • Arizona Clinical Trials

    RECRUITING

    Chandler, Arizona, 85224, United States

  • Biopharma Informatic, LLC

    RECRUITING

    Houston, Texas, 77043, United States

  • Cahaba Research, Inc.

    RECRUITING

    Pelham, Alabama, 35124, United States

  • Centricity Research Morehead City Specialty

    RECRUITING

    Morehead City, North Carolina, 28557, United States

  • Charter Research - The Villages

    RECRUITING

    The Villages, Florida, 32162, United States

  • Clinical Neuroscience Solutions

    RECRUITING

    Orlando, Florida, 32801, United States

  • Desert Oasis Healthcare Medical Group

    RECRUITING

    Palm Springs, California, 92262, United States

  • Eastside Research Associates Health Research

    RECRUITING

    Redmond, Washington, 98052, United States

  • Endeavor Health

    RECRUITING

    Skokie, Illinois, 60077, United States

  • Epic Medical Research - DeSoto

    RECRUITING

    DeSoto, Texas, 75115, United States

  • Epic Medical Research - Oklahoma

    RECRUITING

    Chickasha, Oklahoma, 73018, United States

  • Epic Medical Research - Sun City

    RECRUITING

    Sun City, Arizona, 85351, United States

  • Excel Clinical Research

    RECRUITING

    Las Vegas, Nevada, 89109, United States

  • Florida Institute for Clinical Research

    RECRUITING

    Orlando, Florida, 32825, United States

  • Icahn School of Medicine at Mount Sinai

    RECRUITING

    New York, New York, 10029, United States

  • Inland Empire Liver Foundation

    RECRUITING

    Rialto, California, 92377, United States

  • Lynn Health Science Institute

    RECRUITING

    Oklahoma City, Oklahoma, 73112, United States

  • Montana Medical Research

    RECRUITING

    Missoula, Montana, 59808, United States

  • New Horizon Research Center

    RECRUITING

    Miami, Florida, 33165, United States

  • North Georgia Clinical Research

    RECRUITING

    Woodstock, Georgia, 30189, United States

  • North Hills Medical Research

    RECRUITING

    North Richland Hills, Texas, 76180, United States

  • Northwest Houston Heart Center

    RECRUITING

    Tomball, Texas, 77375, United States

  • Nsc Research

    RECRUITING

    Johns Creek, Georgia, 30024, United States

  • Peninsula Research Associates

    RECRUITING

    Rolling Hills Estates, California, 90274, United States

  • Pennington Biomedical Research Center

    RECRUITING

    Baton Rouge, Louisiana, 70808, United States

  • Progressive Medical Research

    RECRUITING

    Port Orange, Florida, 32127, United States

  • Puerto Rico Medical Research Inc.

    RECRUITING

    Ponce, 00717, Puerto Rico

  • Research Institute of South Florida

    RECRUITING

    Miami, Florida, 33173, United States

  • Research Physicians Network, LLC

    RECRUITING

    Houston, Texas, 77089, United States

  • Rochester Clinical Research

    RECRUITING

    Rochester, New York, 14609, United States

  • Rophe Adult and Pediatric Medicine/Sky Clinical Research Network Group

    RECRUITING

    Union City, Georgia, 30291, United States

  • Sky Integrative Medical Center

    RECRUITING

    Ridgeland, Mississippi, 39157, United States

  • Solaris Clinical Research

    RECRUITING

    Meridian, Idaho, 83646, United States

  • South Florida Clinical Research

    RECRUITING

    Margate, Florida, 33063, United States

  • South Texas Research Institute

    RECRUITING

    Edinburg, Texas, 78539, United States

  • Southern California Clinical Research

    RECRUITING

    Santa Ana, California, 92701, United States

  • Texas Institute of Cardiology

    RECRUITING

    McKinney, Texas, 75071, United States

  • University of Florida Department of Medicine

    RECRUITING

    Gainesville, Florida, 32610, United States

  • VIP Trials

    RECRUITING

    San Antonio, Texas, 78230, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.